2012
DOI: 10.1016/j.jep.2011.11.050
|View full text |Cite
|
Sign up to set email alerts
|

Antiosteoporotic activity of Davallia formosana

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
33
0
2

Year Published

2013
2013
2017
2017

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 31 publications
(35 citation statements)
references
References 26 publications
0
33
0
2
Order By: Relevance
“…Furthermore, biomechanics allow us to identify the biological effects of bone under force or stress [23]. Previous studies have proved that although low bone mass in osteoporotic bones is a major risk factor for the occurrence of a fracture, the presence of adequate trabecular microstructure can preserve the biomechanical properties of the bone [25,26].…”
Section: Discussionmentioning
confidence: 99%
“…Furthermore, biomechanics allow us to identify the biological effects of bone under force or stress [23]. Previous studies have proved that although low bone mass in osteoporotic bones is a major risk factor for the occurrence of a fracture, the presence of adequate trabecular microstructure can preserve the biomechanical properties of the bone [25,26].…”
Section: Discussionmentioning
confidence: 99%
“…According to previously method, 16 Prior to mechanical testing, the right femurs were collected and stored at 37 °C until the day of test. Briefly, the length of the femurs was first measured with a micrometer and the middle part of the diaphysis.…”
Section: Discussionmentioning
confidence: 99%
“…Two weeks after recovering from surgery, the OVX rats were randomly divided into six groups: OVX/Mock, OVX/1X kefir (164 mg/kg BW/day), OVX/2X kefir (328 mg/kg BW/day), OVX/4X kefir (656 mg/kg BW/day), OVX/ALN (2.5 mg/kg BW/day), and OVX/REBONE (800 mg/kg BW/day). The daily doses of kefir and ALN were based on the doses of the references [12,21], and REBONE was based on prescription drug information. An aminobisphosphonate (ALN) employed as an antiresorptive agent in the treatment of osteoporosis was used as a positive therapy control.…”
Section: Ovariectomy Protocol and Groupsmentioning
confidence: 99%